Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER HER2 locally-advanced or metastatic breast cancer

Journal:

Nature Communications

Published:

2026-04-01

DOI:

10.1038/s41467-026-71233-1

Affiliations:

14

Authors:

19

Go to article

Institutions	Authors	Share
Genentech, Inc., United States of America (USA)	16.000000 16.000000	0.84
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	0.500000	0.03
Weill Cornell Medicine, United States of America (USA)	0.500000	0.03
The Royal Marsden Hospital - London, The Royal Marsden NHS Foundation Trust, United Kingdom (UK)	0.500000	0.03
The Institute of Cancer Research (ICR), United Kingdom (UK)	0.500000	0.03
St Vincent's Hospital Sydney, Australia	0.333333	0.02
University of New South Wales (UNSW Sydney), Australia	0.333333	0.02
Garvan Institute of Medical Research, Australia	0.333333	0.02

Interested in Oncology and Carcinogenesis?